Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals International, plc (Exact name of registrant as specified in its charter) England an ...

Financial Performance - UFP Technologies reported 2025 net income of $68.3 million, a 15.8% increase from $59.0 million in 2024[2] - Net sales for 2025 reached $602.8 million, up 19.5% from $504.4 million in 2024, driven by a 23.2% increase in medical sales[4] - Adjusted net income for 2025 grew 12.7% to $76.1 million from $67.6 million in 2024[5] - Operating income for 2025 increased 14.1% to $92.3 million, despite $6.3 million in labor-related inefficiencies[4] - Fourth quarter sales increased 3.4% to $148.9 million compared to $144.1 million in Q4 2024[5] - Adjusted operating income for the year ended December 31, 2025, was $102.874 million, up from $92.302 million in 2024[26] - Adjusted net income for the three months ended December 31, 2025, was $19.034 million, compared to $19.163 million for the same period in 2024[28] - Adjusted EBITDA for 2025 increased to $121.1 million from $107.3 million in 2024[6] - Adjusted EBITDA for the year ended December 31, 2025, was $121.100 million, compared to $107.321 million in 2024[30] Cost and Margin Analysis - Gross margin for 2025 decreased to 28.3% from 29.1% in 2024, impacted by labor costs at the AJR facility[5] - SG&A expenses for 2025 rose 24.5% to $77.4 million, with SG&A as a percentage of sales increasing to 12.8%[5] - Adjusted gross margin for the three months ended December 31, 2025, was 28.2%, compared to 29.2% for the same period in 2024[22] Acquisitions and Expansion - The company completed four acquisitions in 2024 and three in 2025, with integrations progressing well[4] - UFP Technologies plans to expand operations in the Dominican Republic, including new facilities and contract extensions[4] - The company is focused on identifying suitable acquisition candidates and integrating them effectively[16] Future Outlook - The company expects an increase in revenue due to new robotic programs and facility expansions[16] - The company anticipates improved profitability at its Illinois facility and successful program transfers to the Dominican Republic[16] Risks and Challenges - Risks include customer concentration, potential delays in production, and challenges in executing business plans[16] - Organic sales growth rate for the year ended December 31, 2025, was 1.5%, while the three months ended December 31, 2025, showed a decline of 0.03%[20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 _____________________________ AbCellera Biologics Inc. (Exact name of Registrant as specified in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35370 Luxfer Holdings PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 98-1024030 State or Other Jurisdiction of Incorporation or Organization WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 I.R.S. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 10-K ______________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ______ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR (I.R.S. Employer Identification No.) Sunnyvale, CA 94085 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (800) 436-0826 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-08089 DANAHER CORPORATION (Exact name of registrant as specified in its charter) Delaware 59-19 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39413 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 23-2081753 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) ...

Revenue Performance - Revenue for Q4 2025 was $574.5 million, representing a 5.3% year-over-year increase and a 2.7% increase in constant currency[4]. - Full-year 2025 revenue decreased to $1.95 billion, down 2.9% year-over-year and 3.3% in constant currency[6]. - Revenue for Q4 2025 was $574.5 million, an increase from $545.4 million in Q4 2024, while full-year revenue decreased to $1,950.1 million from $2,008.4 million in 2024[39]. - Total revenue for the year ended December 31, 2025, was $1,950.1 million, a decrease of 2.9% from $2,008.4 million in 2024[42]. - The company achieved revenue of $574.5 million in Q4 2025, an increase from $545.4 million in Q4 2024, but a decline from $2,008.4 million in the year ended 2024 to $1,950.1 million in 2025[55]. Profitability Metrics - Non-GAAP operating profit margin for Q4 2025 was 18.0%, an increase of 640 basis points year-over-year[4]. - Operating income for Q4 2025 was $76.6 million, compared to $48.6 million in Q4 2024, with a full-year operating income of $78.5 million down from $97.4 million in 2024[39]. - Consolidated net earnings for Q4 2025 were $19.8 million, a decrease from $30.5 million in Q4 2024, leading to a full-year net loss of $340.0 million compared to a loss of $193.2 million in 2024[39]. - Basic earnings per share for Q4 2025 was $0.26, down from $0.43 in Q4 2024, with a full-year loss per share of $(4.79) compared to $(2.79) in 2024[39]. - Non-GAAP net income attributable to Unisys Corporation was $63.4 million for Q4 2025, significantly higher than $26.6 million in Q4 2024, with a yearly increase from $44.0 million in 2024 to $68.3 million in 2025[51]. Cash Flow and Financial Position - Cash provided by operations in Q4 2025 was $104.9 million, up from $76.6 million in Q4 2024[19]. - Free cash flow for Q4 2025 increased by $30.1 million year-over-year, primarily due to lower net interest payments and increased license renewals collections[19]. - Cash and cash equivalents increased to $421.7 million as of December 31, 2025, from $390.6 million at the end of 2024[48]. - Long-term debt rose to $729.0 million as of December 31, 2025, compared to $488.2 million in 2024[46]. - Free cash flow for Q4 2025 was $85.8 million, up from $55.7 million in Q4 2024, while the yearly free cash flow showed a decline from $(217.6) million in 2025 compared to $55.3 million in 2024[53]. Contract Value and Backlog - Total Contract Value (TCV) for Q4 2025 was $1.149 billion, a 53% increase year-over-year[22]. - Backlog increased to $3.16 billion in Q4 2025, compared to $2.84 billion in Q4 2024, driven by Ex-L&S renewal signings[23]. - New Business TCV for FY25 was $491 million, a 38% decrease year-over-year[22]. - The company reported a backlog of contracted work, which is a key indicator of future revenue, although specific figures were not disclosed[28]. - Total Contract Value (TCV) is a significant metric for assessing future revenue potential, with new business TCV representing expansion and new contracts[28]. Future Guidance and Strategic Focus - The company provided 2026 revenue growth guidance of (6.5)% to (4.5)% in constant currency[23]. - The company anticipates revenue growth and margin expansion in 2026, with guidance provided during the conference call[30]. - Free cash flow generation is a focus area, with adjusted free cash flow metrics being highlighted for investor transparency[32]. - The company continues to invest in technology solutions, including cloud and AI, to drive future growth and operational efficiencies[35]. Pension and Other Expenses - The defined benefit pension plans funding deficit improved to $448.5 million, a reduction of $301.7 million year-over-year[18]. - The company reported a pension and postretirement expense of $22.2 million for Q4 2025, up from $11.1 million in Q4 2024, with a yearly expense of $309.0 million in 2025 compared to $182.2 million in 2024[55].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2025 or Commission File Number: 1-6887 BANK OF HAWAII CORPORATION (Exact name of registrant as specified in its charter) | Delaware | 99-0148992 | | --- | --- | | (State of incorporation) | (I.R.S. Employer Identification No.) | 130 Merchant Street Honolulu Hawaii 96813 (Add ...